DanCann Pharma A/S to be inspected by the Danish Medicines Agency in Q4 2022: EU-GMP approval expected by the end of 2022

copenhagen denmark, November 8, 2022 – Duncan Pharma A/S (SS: DANCAN) (“DanCann Pharma” or the “Company”), a Danish cannabinoid-based company, expects to obtain EU-GMP approval for its Biotech Pharm1 (“BP1”) production facility in the fourth quarter We hereby announce that 2022.

earlier this year Duncan Pharma We have applied for approval of the production facility BP1. Danish medical institution has informed the company that the inspection will take place in the fourth quarter of 2022.Approval will be the most important milestone so far Duncan Pharma It opens up further market possibilities for our company.

during 2022 Duncan Pharma I’ve run quite a few tests with Ansager’s BP1. At the same time, the company has optimized all processes and systems to comply with medical cannabis production requirements. Denmark When Europe.

The company is now ready for inspection. Danish Medicines Agency To be approved according to EU-GMP standards. Approval is expected to take place in 2022.

Jeppe Krog Rasmussen CEO of Duncan Pharma,comment:

– EU-GMP certification of a facility is recognition of our work and is an important step in achieving quality-assured products for our partners and ultimately patients. This is essential to our legitimacy in the market. By focusing on unified product content and delivering the same quality every time, Duncan Pharma It is obligatory to administer to patients who can benefit from treatment with medical cannabis and cannabinoids. Duncan Pharma Founded to make a difference for patients.

BP1 is built on pharmaceutical industry best practices that combine advanced controlled-environment manufacturing techniques with vertical cultivation. Selected genetics are developed in a multi-layered system without the use of soil or other media, but with a specially developed system that adds the required amount of liquids and nutrients.

Jeppe Krog Rasmussen comment:

– Acknowledgment marks an important and decisive step in the journey. Duncan Pharma – Something we have been working on for a long time. Duncan Pharma We are on the verge of moving from project to production.We are ready to make a visible impact on the medical cannabis market Denmark and Europe.

After facility approval, Duncan Pharma is facing its biggest milestone yet, with the first batch of biomaterials ready to ship from BP1 in the first half of 2023.

about Duncan Pharma

Duncan Pharma A/S (SS: DANCAN) is a Danish cannabinoid-based biopharmaceutical company founded in 2018. Duncan Pharma is a vertically integrated licensed manufacturing and distribution company based in DenmarkThe Company focuses on the discovery, development, manufacturing and commercialization of new therapeutic cannabinoids in a wide range of disease areas.

Duncan Pharma A/S (SS: DANCAN) listed spotlight stock market of copenhagen.

For more information, please visit www.dancann.com.

For more information, please contact:

Jeppe Krog RasmussenCEO

Email: jkr@dancann.com

Website: www.dancann.com

Disclaimer

Certain statements in this release may contain forward-looking information. All statements, other than historical facts, that address future activities, events or developments that the Company believes, expects or anticipates will occur or may occur (potential acquisitions and financing statements, including but not limited to statements regarding, are forward-looking statements. statement. Forward-looking statements generally use the words “may,” “will,” “should,” “continue,” “expect,” “project,” “estimate,” and “believe.” ‘, ‘intend’, and ‘plan’. ‘ or ‘project’, or the negation of these words, or other variations of these words, or equivalent terms.

Forward-looking statements are subject to a number of risks and uncertainties. Many of these are beyond our ability to control or predict and could cause our actual results to differ materially from those set forth in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, our inability to obtain sufficient funds to execute our business plans; is not limited to competition; regulatory and anticipated and unanticipated costs and delays, success of the company’s research strategy, applicability of discoveries made therein, successful and timely completion and uncertainty related to the regulatory process, regulatory or intellectual the timing and consequences of property decisions and other risks disclosed in our public disclosure records filed with relevant securities regulators;

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those set forth in the forward-looking statements, it is Or there may be other factors that cause it to be different than intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements contained in this presentation are made as of the date of this presentation and the Company may not reflect new information, subsequent events or otherwise, unless required by applicable securities laws. does not undertake any obligation to publicly update such forward-looking statements.

https://news.cision.com/dancann-pharma/r/dancann-pharma-as-with-inspection-by-the-danish-medicine-agency-during-q4-2022–expects-to-get-eu -g,c3663148

https://mb.cision.com/Main/19875/3663148/1654724.pdf

(c) Sision 2022. all rights reserved.sauce Press Release – English